Papers by Hagop M. Kantarjian
Page 14 · newest first
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic LeukemiaNew England Journal of Medicine · 2016
- Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD)Leukemia · 2016
- Vosaroxin: innovative anticancer quinolone for the treatment of acute myelogenous leukemiaExpert Opinion on Orphan Drugs · 2016
- Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemiaBlood · 2016
- Malignancy‐associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomesCancer · 2016
- Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemiaBlood · 2016
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients TrialJournal of Clinical Oncology · 2016
- Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibitionSHILAP Revista de lepidopterología · 2016
- Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.Journal of Clinical Oncology · 2016
- Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034American Journal of Hematology · 2016
- Final results of a single institution experience with a pediatric‐based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper‐CVAD regimenAmerican Journal of Hematology · 2016
- Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysisHaematologica · 2016
- Phase I study of evofosfamide, an investigational hypoxia‐activated prodrug, in patients with advanced leukemiaAmerican Journal of Hematology · 2016
- Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapyBlood Cancer Journal · 2016
- Blinatumomab treatment of older adults with relapsed/refractory B‐precursor acute lymphoblastic leukemia: Results from 2 phase 2 studiesCancer · 2016
- Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemiaLeukemia · 2016
- Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD–Positive Acute Myelogenous LeukemiaBiology of Blood and Marrow Transplantation · 2016
- Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapyBlood · 2016
- Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignanciesCancer · 2016
- The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failureHaematologica · 2016
- Long‐term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome‐positive leukemias treated with bosutinibAmerican Journal of Hematology · 2016
- Acute myeloid leukemia: advancing clinical trials and promising therapeuticsExpert Review of Hematology · 2016
- ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignanciesScience Signaling · 2016
- Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agentsOncotarget · 2016
- Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomesBritish Journal of Haematology · 2016
- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trialLeukemia · 2016
- Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoringAmerican Journal of Hematology · 2016
- Design of the Randomized, Phase III, QUAZAR AML Maintenance Trial of CC-486 (Oral Azacitidine) Maintenance Therapy in Acute Myeloid LeukemiaFuture Oncology · 2016
- Role of Inotuzumab Ozogamicin in the Treatment of Relapsed/Refractory Acute Lymphoblastic LeukemiaImmunotherapy · 2016
- Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtypeBlood · 2016
- Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML)Clinical Lymphoma Myeloma & Leukemia · 2016
- Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitorsBlood · 2016
- CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast countLeukemia & lymphoma/Leukemia and lymphoma · 2016
- The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapyCancer · 2015
- Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analysesBlood Cancer Journal · 2015
- Rituximab plus hyper‐CVAD alternating with MTX/Ara‐C in patients with newly diagnosed mantle cell lymphoma: 15‐year follow‐up of a phase II study from the MD Anderson Cancer CenterBritish Journal of Haematology · 2015
- Characterization of Fever, Infection, and Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with BlinatumomabBlood · 2015
- The Impact of Anemia on Overall Survival in Patients with Myelofibrosis Treated with Ruxolitinib: An Exploratory Analysis of the Comfort StudiesBlood · 2015
- Clinical and Molecular Characterization of p53-Mutated Acute Myeloid LeukemiaBlood · 2015
- Safety, Pharmacokinetics, and Efficacy of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)Blood · 2015
- Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 TrialBlood · 2015
- Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)Blood · 2015
- Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19+ MalignanciesBlood · 2015
- Qualitative and Quantitative Correlation of PML-Rara Fusion Transcript from Peripheral Blood and Bone Marrow Samples By Quantitative Real-Time PCR in Patients with Acute Promyelocytic LeukemiaBlood · 2015
- Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE TrialBlood · 2015
- MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199Cell Reports · 2015
- Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsBlood · 2015
- Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)American Journal of Hematology · 2015
- Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid LeukemiaJNCI Journal of the National Cancer Institute · 2015
- Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinibBritish Journal of Haematology · 2015